ST Welfare: HW252001 received the drug clinical trial approval letter.

ST Group Announcement: Recently, the wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., received the "Notice of Approval for Drug Clinical Trial" for the HW252001 tablet issued by the National Medical Products Administration. The HW252001 tablet is intended for the treatment of idiopathic pulmonary fibrosis and is a new oral small molecule drug. Up to now, the cumulative research and development investment in this project is approximately 20 million RMB.